BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38542081)

  • 21. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in
    Imbert-Bouteille M; Corsini C; Picot MC; Mizrahy L; Akouete S; Huguet H; Thomas F; Geneviève D; Taourel P; Ychou M; Galibert V; Rideau C; Baudry K; Kogut Kubiak T; Coupier I; Hobeika R; Macary Y; Toledano A; Solassol J; Maalouf A; Daures JP; Pujol P
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutional Mosaic Epimutations - a hidden cause of cancer?
    Lønning PE; Eikesdal HP; Løes IM; Knappskog S
    Cell Stress; 2019 Mar; 3(4):118-135. PubMed ID: 31225507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
    Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
    Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
    Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of promoter methylation patterns association with genes expression profile of ISL1, MGMT and DMNT3b in tissue of breast cancer patients.
    Yari H; Shabani S; Nafissi N; Majidzadeh T; Mahjoubi F
    Mol Biol Rep; 2022 Feb; 49(2):847-857. PubMed ID: 34997427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.
    Hawkins NJ; Lee JH; Wong JJ; Kwok CT; Ward RL; Hitchins MP
    Mod Pathol; 2009 Dec; 22(12):1588-99. PubMed ID: 19734844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline variation in O
    Belhadj S; Moutinho C; Mur P; Setien F; Llinàs-Arias P; Pérez-Salvia M; Pons T; Pineda M; Brunet J; Navarro M; Capellá G; Esteller M; Valle L
    Cancer Lett; 2019 Apr; 447():86-92. PubMed ID: 30677446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
    Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
    Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated
    Al-Moghrabi N; Al-Showimi M; Al-Yousef N; AlOtai L
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
    Lønning PE; Knappskog S
    Clin Epigenetics; 2018 Oct; 10(1):128. PubMed ID: 30348217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.